DelveInsight’s “Thrombocytopenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Thrombocytopenia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Thrombocytopenia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Thrombocytopenia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Thrombocytopenia: An Overview
Thrombocytopenia is a medical condition in which the platelet count in the blood falls (<150,000/µL of circulating blood) below the normal value. The etiology of thrombocytopenia is vast as many conditions may lead to low platelet count in the blood. The most common etiologies are heparin-induced thrombocytopenia, chemotherapy-induced thrombocytopenia, thrombocytopenia associated with chronic liver disease, immune thrombocytopenia (ITP), and thrombotic thrombocytopenic purpura (TTP).
Thrombocytopenia often improves when its underlying cause is treated. People who inherit the condition do not usually need treatment. If a reaction to a medicine is causing a low platelet count, the doctor may prescribe another medicine. Most people recover after the initial medicine has been stopped. For heparin-induced thrombocytopenia (HIT), stopping the heparin is not enough. Often, the patients need another medicine to prevent blood clotting. If the immune system is causing a low platelet count, the doctor may prescribe medicines to suppress the immune system.
Thrombocytopenia can result from decreased platelet production, increased platelet consumption, or sequestration. A systematic approach should be used to evaluate incidental thrombocytopenia. Physicians should inquire about easy bruising or petechiae, melena, rashes, fevers, and bleeding during the patient’s history. They also should inquire about medication use, immunizations, recent travel, transfusion history, family history, and medical history. A history of acute and chronic alcohol use should be obtained. Any recent hospitalization or heparin exposure should raise the possibility of heparin-induced thrombocytopenia.
Thrombocytopenia Market Key Facts
-
In 2021, the US has the largest Thrombocytopenia market size of USD 2,447 million among the 7MM countries.
-
Among the EU-5 countries, Germany had the highest Thrombocytopenia market size in 2021, i.e., USD 431 million. The lowest Thrombocytopenia market size was estimated in France, with USD 242 million in 2021.
-
In Japan, the Thrombocytopenia market size was observed to be USD 328 million in 2021.
-
In 2021, the total cases of Thrombocytopenia in the 7MM countries were 2,608,095, and these cases are anticipated to increase during the study period. The US accounted for 1,045,247 cases of Thrombocytopenia in 2021.
-
Among the European countries, Germany had the highest number of cases of Thrombocytopenia in 2021, i.e., 453,441 cases, followed by the UK which had 269,422 cases in 2021. On the other hand, Italy had the lowest number of cases of Thrombocytopenia, i.e. 127,166 cases in 2021.
-
The highest cases of TTP were seen in the US, which accounted for 6,002 cases in 2021.
-
Japan, in 2021, accounted for 58,261 cases of Chemotherapy-induced Thrombocytopenia, which is expected to increase during the study period.
-
The maximum number of cases of Heparin-induced Thrombocytopenia in 2021 was recorded in Germany out of all the EU-5 countries, and Spain accounted for the least number of cases.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Thrombocytopenia pipeline therapies. It also thoroughly assesses the Thrombocytopenia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Thrombocytopenia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Thrombocytopenia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Thrombocytopenia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Thrombocytopenia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Thrombocytopenia Epidemiology, Segmented as –
-
Total Cases of Thrombocytopenic Purpura (TTP)
-
Total Cases of Immune Thrombocytopenia (ITP)
-
Total Cases of Thrombocytopenia in Chronic Liver Disease
-
Total Cases of Chemotherapy-induced Thrombocytopenia
-
Total Number of Cases of Heparin-induced Thrombocytopenia
-
Total Cases of Thrombocytopenia Scenario
Thrombocytopenia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Thrombocytopenia market or expected to be launched during the study period. The analysis covers the Thrombocytopenia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Thrombocytopenia drugs based on their sale and market share.
The report also covers the Thrombocytopenia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Thrombocytopenia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Thrombocytopenia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/thrombocytopenia-market
Thrombocytopenia Therapeutics Analysis
Corticosteroids are the most commonly used first-line therapy for ITP. Treatment is initiated with prednisolone or prednisone (1–2 mg/kg per day, p.o., single or divided doses). In general, corticosteroids are initially effective. A study comparing high- and low-dose corticosteroids in adult patients found that low-dose therapy was initially more effective, although long-term effects have not been determined.
The approved therapies for treating thrombocytopenia in the US include MULPLETA, DOPTELET, TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. These therapies are approved for various patient groups; for example, MULPLETA and DOPTELET are approved for thrombocytopenia in chronic liver disease, PROMACTA is approved for chronic immune (idiopathic) thrombocytopenic purpura (ITP).
The approved therapies in the EU include MULPLETA/MULPLEO (lusutrombopag), DOPTELET (avatrombopag), TAVALISSE/TAVLESSE (fostamatinib), PROMACTA/REVOLADE (eltrombopag), NPLATE/ROMIPLATE (romiplostim), and CABLIVI (caplacizumabum).
OCTAGAM, RHOPHYLAC, and PRIVIGEN are the immunoglobulins approved in the EU to treat immune thrombocytopenic purpura.
The approved medications in Japan for the treatment of thrombocytopenia include various etiologies like MULPLETA/ MULPLEO (lusutrombopag), PROMACTA/REVOLADE (eltrombopag), NPLATE/ROMIPLATE (romiplostim), and RITUXAN (rituximab).
To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Thrombocytopenia. Currently, Argenx is leading the therapeutics market with its Thrombocytopenia drug candidates in the most advanced stage of clinical development.
Thrombocytopenia Companies Actively Working in the Therapeutics Market Include
Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo, and others.
Emerging and Marketed Thrombocytopenia Therapies Covered in the Report Include:
-
Efgartigimod alfa – Argenx
-
Rozanolixizumab: UCB
-
Cevidoplenib: Genosco
-
Sovleplenib: HUTCHMED
-
TAK-755: Baxalta/Takeda
-
Rilzabrutinib: Sanofi/Principia Biopharma
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/thrombocytopenia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Thrombocytopenia Competitive Intelligence Analysis
4. Thrombocytopenia Market Overview at a Glance
5. Thrombocytopenia Disease Background and Overview
6. Thrombocytopenia Patient Journey
7. Thrombocytopenia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Thrombocytopenia Treatment Algorithm, Current Treatment, and Medical Practices
9. Thrombocytopenia Unmet Needs
10. Key Endpoints of Thrombocytopenia Treatment
11. Thrombocytopenia Marketed Therapies
12. Thrombocytopenia Emerging Drugs and Latest Therapeutic Advances
13. Thrombocytopenia Seven Major Market Analysis
14. Attribute Analysis
15. Thrombocytopenia Market Outlook (In US, EU5, and Japan)
16. Thrombocytopenia Companies Active in the Market
17. Thrombocytopenia Access and Reimbursement Overview
18. KOL Views on the Thrombocytopenia Market
19. Thrombocytopenia Market Drivers
20. Thrombocytopenia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/thrombocytopenia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Juvenile Idiopathic Arthritis (JIA) Market
“Juvenile Idiopathic Arthritis (JIA) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Juvenile Idiopathic Arthritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Juvenile Idiopathic Arthritis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research